Your browser doesn't support javascript.
loading
Mesenchymal stem cell-based TRAIL delivery inhibits the metastatic state of clinical therapy-resistant progressive neuroblastoma.
Somasundaram, Dinesh Babu; Maher, Andrew; Aravindan, Sheeja; Yu, Zhongxin; Besch, Brian M; Aravindan, Natarajan.
Affiliation
  • Somasundaram DB; Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Maher A; Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Aravindan S; Stephenson Cancer Center, Oklahoma City, OK, USA.
  • Yu Z; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Besch BM; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Aravindan N; Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. naravind@ouhsc.edu.
World J Pediatr ; 20(3): 287-293, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38060141
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mesenchymal Stem Cells / Neuroblastoma Limits: Humans Language: En Journal: World J Pediatr Journal subject: PEDIATRIA Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mesenchymal Stem Cells / Neuroblastoma Limits: Humans Language: En Journal: World J Pediatr Journal subject: PEDIATRIA Year: 2024 Type: Article Affiliation country: United States